Sign In

Search Press
Looking for press releases of a particular company? Enter company name (or keyword) here.


Generic drugs contract manufacturer Dragenopharm acquired by Bridgepoint

01/03/2007 -- European private equity firm Bridgepoint has taken a majority stake in Dragenopharm Apotheker Püschl GmbH, a leading German contract manufacturing organisation for the European generic prescription drug market, for an undisclosed sum.

Headquartered in Bavaria, Dragenopharm specialises in the production and packaging of solid dosage form and has a portfolio of more than 1,000 different products. The company has four sites in Germany and has the largest manufacturing capacity for the production of solid dosage forms and coating of tablets and tabletting in Europe. In 2006, output is estimated to have exceeded five billion tablets, with sales of approximately €68 million.

Germany is the largest pharmaceutical market in Europe as well as being the largest for non-patented prescription drugs whose sales are estimated to be worth €5.3 billion annually. Dragenopharm's customers are the leading German generic and dietary supplement companies, many of whom are focussed on export as well as domestic sales.

“Dragenopharm has delivered strong growth in its core home market as well as internationally thanks to a combination of competitive pricing, the quality of its product range and superior manufacturing infrastructure,” said Uwe Kolb, partner responsible for Bridgepoint in Germany.

“We expect the company to grow further in line with the strong outlook for the generic drug sector, in particular as generic drug penetration rates are expected to increase substantially across a range of European countries.” he said.

He added: “The acquisition of Dragenopharm underlines the strong market position of Bridgepoint in the German Mittelstand and the confidence family owners have in Bridgepoint as responsible owners”

Dr. Andreas Greither, CEO of Dragenopharm, said: “We are now entering the next investment phase in the history of our company and welcome Bridgepoint as an important investor in the future growth of our business.”

“We operate in a dynamic market where our expertise and our people have earned us a loyal and growing customer base and for which we predict a strong and sustainable growth outlook” he said.

Advisers involved in this transaction include: for Bridgepoint – Clifford Chance (legal), KPMG (accounting), LEK (commercial due diligence) and PWC (tax); for the vendor – Schober Eiche & Co. (corporate finance), Heiss & Partner (legal) and Ernst & Young (tax).

Publisher Contact Information:

Bridgepoint Capital Ltd
+44 (0) 20 7432 3555

Company profile of Bridgepoint Capital Ltd
Past press releases of Bridgepoint Capital Ltd.


Tech investments
From our Online Data Service
VC-backed companies
From our Radar

Recent Deals

Nov 15€2.4MMaterials
Nov 15€6.0MArtificial Intelligence
Nov 15€3.5MSoftware development
Nov 15N/AInternet services
Nov 14€4.5MOther Software
Nov 14€4.7MBusiness applications
Nov 14€9.0MKnowledge management

For information on Europe's most extensive database on technology funding click here!


Press Releases

May 28
identiq raises $5m seed, launches privacy-first identity validation...

Apr 29
nethone raised over $1 million from innovation nest

Oct 1
The Link App
the link app launches version 2.0

Mar 29
Addex Therapeutics
addex sucessfully raises chf40 million in capital increase

Jan 2
Urban Jungle
urban jungle raises £1m in seed funding to build tech-enabled home ...

About usContact usLegal Information
Copyright © 1999-2019
Emerging Technology Research Europe Inc. All rights reserved.